Olema Pharmaceuticals, Inc. SEC Filings

Olema Pharmaceuticals executive David C. Myles reported multiple stock option exercises and share sales. On January 13 and 14, he exercised a total of 100,000 stock options at an exercise price of $4.87 per share, resulting in 50,000 stock options remaining outstanding. Over January 13–14, he sold 100,000 shares of common stock in the market at weighted average prices ranging from $27.60 to $28.99 per share, leaving 542,761 shares held directly.

An entity associated with him, Myles Properties Inc., sold 10,000 shares on January 12 at a weighted average price of $28.34, and continued to hold 144,846 shares indirectly. A family trust associated with him held an additional 12,831 shares indirectly. The filing also notes that a prior Form 4 overstated his directly owned shares by 120 shares due to a scrivener's error, which is corrected here.

Cyrus L. Harmon has filed a notice of proposed sale of 3,489 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services LLC on or about 01/14/2026 on the NASDAQ market. Based on the figures provided, the aggregate market value of the planned sale is $101,603.33, and the issuer has 68,659,923 shares of common stock outstanding.

The shares to be sold were originally acquired as founder shares on 03/20/2007 as compensation from the issuer. Over the past three months, Harmon has already sold 2,881 common shares on 12/22/2025 for gross proceeds of $82,182.00. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.

OLMA shareholder David C. Myles has filed a notice of proposed sale of 50,000 shares of common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an indicated aggregate market value of $1,443,631.44 and 68,659,923 common shares outstanding.

The 50,000 shares relate to an option granted on 02/01/2023 and acquired on 01/14/2026, with the purchase price paid in cash. The notice also reports other sales during the past three months, including 51,000 common shares sold by David C. Myles on 12/19/2025 for $1,553,447.42, 10,000 common shares sold by Myles Properties, Inc on 01/12/2026 for $283,362.96, and 50,000 common shares sold by David C. Myles on 01/13/2026 for $1,380,115.00.

A shareholder in OLMA has filed a Form 144 notice covering a potential sale of 3,822 shares of common stock through Fidelity Brokerage Services on the NASDAQ market, with an aggregate market value of $107,069.20 as reported. The notice states that 68,659,923 shares of this class are outstanding. The shares to be sold were acquired through employee-related transactions, including ESPP purchases on 05/14/2021 and 11/15/2021 totaling 2,517 shares for cash, and 1,305 shares received via restricted stock vesting on 12/09/2024 as compensation.

An insider has filed a Rule 144 notice to sell 50,000 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,380,112.65. The shares relate to common stock where the number of shares outstanding is listed as 68,659,923, and the approximate sale date is given as 01/13/2026.

The securities to be sold were acquired on 01/13/2026 via an option granted on 02/01/2023, with 50,000 shares acquired for cash. Over the past three months, the notice reports prior sales of 51,000 common shares on 12/19/2025 for gross proceeds of $1,553,447.42 by David C. Myles and 10,000 common shares on 01/12/2026 for gross proceeds of $283,362.96 by Myles Properties, Inc. The signer represents that they do not know of any undisclosed material adverse information about the issuer’s operations.

Olema Pharmaceuticals reported that its preliminary, unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were greater than $500 million. This early estimate is based on year-end data but may change once the company completes its full financial closing procedures and audit for the 2025 fiscal year.

The company emphasized that this cash figure is preliminary, unaudited, and should not replace the detailed financial statements that will appear in its upcoming annual report on Form 10-K. Olema also posted an investor presentation on its website and furnished it as an exhibit, providing additional background for investors and other stakeholders.

OLMA received a Form 144 notice indicating an intent to sell up to 10,000 shares of its common stock through Fidelity Brokerage Services LLC on or about 01/12/2026 on the NASDAQ market, with an aggregate market value of $283,362.96 at the time of the notice. These 10,000 shares were originally acquired on 06/30/2014 from the issuer via a convertible note transaction paid in cash. The notice also reports that security holder David C. Myles sold 51,000 common shares on 12/19/2025 for gross proceeds of $1,553,447.42. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s operations.

Olema Pharmaceuticals, Inc. director reported an option exercise and a subsequent charitable gift of common stock. On 11/21/2025, the reporting person exercised a stock option and acquired 35,868 shares of Olema common stock at an exercise price of $0.39 per share. After this exercise, the same number of shares was held directly.

On 11/25/2025, the reporting person transferred 35,868 shares as a bona fide gift for no consideration to the Rappaport Family Foundation, a charitable foundation where the reporting person serves as an officer and has voting and dispositive power over the securities it owns. Following the reported transactions, the reporting person no longer holds Olema shares directly but reports 385,965 shares held indirectly through the Rappaport Family Trust, of which the reporting person is co‑trustee.

Olema Pharmaceuticals, Inc. (OLMA) announced a follow-on public offering of 10,000,000 shares of common stock at $19.00 per share under an existing shelf registration. The company expects the offering to close on November 20, 2025, subject to customary conditions, and has granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price less underwriting discounts and commissions.

The transaction is expected to generate approximately $190.0 million in gross proceeds for Olema before underwriting discounts, commissions, and estimated expenses, assuming the underwriters do not exercise their option. The deal is led by TD Securities (USA) LLC as representative of the underwriters, and Olema has provided customary representations, warranties, indemnification and closing conditions as part of the underwriting agreement.